Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Diamyd Medical advances U.S. phase III trial of Diamyd for diabetes type 1

March 11, 2010

Actelion receives FDA's complete response letter on Zavesca sNDA for Niemann-Pick type C disease

March 11, 2010

DDP IV inhibitor ASP-4000 has long-lasting effects in preclinical studies

March 11, 2010

Omthera to advance Epanova for hypertriglyceridemia

March 10, 2010

Bristol-Myers and AstraZeneca begin phase IV Onglyza trial

March 10, 2010

Merck KGaA discloses novel tyrosine kinase inhibitors

March 10, 2010

Ulipristal noninferior to levonorgestrel for emergency contraception

March 9, 2010

FDA accepts for review Biodel's VIAject NDA for diabetes

March 8, 2010

Menarini and Ipsen launch febuxostat in France for chronic hyperuricemia in gout

March 8, 2010

Merck & Co. reports new potent and selective GPR109A agonist

March 5, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...